ArticleClinical and experimental medicine2026
MFAP4 promotes cell prognosis of non-small cell lung cancer through the inhibition of ferroptosis by FAK.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, accounting for 80% of lung cancer types, with a high metastasis rate and mortality. Here, this experiment investigated the effects of MFAP4 in NSCLC and its molecular mechanisms of ferroptosis in NSCLC. Patients with NSCLC and normal volunteer were obtained from our hospital. The mRNA and protein expression levels of MFAP4 were upregulated in a mouse model of NSCLC. MFAP4 expression levels in cancer cells of NSCLC model through Single Cell Analysis. Sh-MFAP4 reduced cancer growth, and increased Mitochondrial oxidation-induced ferroptosis in mice model of cancer. MFAP4 promoted cell growth, and reduced Mitochondrial oxidation of NSCLC. Si-MFAP4 increased Mitochondrial oxidation of NSCLC. MFAP4 induced FAK expression of NSCLC through the inhibition of FAK Ubiquitination. The m6A/METTL3 modifies MFAP4 expression stability in model of NSCLC by YTHDF1. In conclusion, MFAP4 induced FAK expression to reduce Mitochondrial oxidation-induced ferroptosis of NSCLC model through the inhibition of FAK Ubiquitination. Targeting MFAP4 is thus a potentially effective therapeutic strategy for patients with NSCLC or other cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.